SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid debates over its valuation following earnings, with community members pointing to its high P/E ratio while others defend its growth potential and strategic positioning in AI. Discussions also involve commentary from CEO Alex Karp and contrasting opinions on the stock's future, including Michael Burry's short position. Overall, the conversation reflects uncertainty about whether Palantir's current market price aligns with its long-term prospects.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid community discussion around a failed confirmatory trial for its PMO therapies, overshadowing otherwise positive earnings reports. Investors are weighing the implications of the trial results on future revenue, particularly in light of Elevidys sales and potential impacts on payer coverage.  Debate centers on whether the market reaction is an overcorrection and if long-term prospects remain strong due to potential buyouts or positive developments in the pipeline.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid mixed sentiment following earnings, with community discussions focusing on revenue beats versus EPS miss and potential risks related to debt and dilution. While some traders are securing profits, others see the dip as a buying opportunity, especially with ongoing developments in nuclear energy and rare earth elements. The stock's movement is also influenced by broader geopolitical factors affecting the rare earth sector.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss the potential impact of earnings results and a possible collaboration with Novo Nordisk. Community members are weighing the company's growth prospects amid concerns about profitability and regulatory pressures. Discussions also focus on potential short squeezes and the influence of institutional investors.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to concerns around increased AI spending and uncertain monetization, sparking worry about future profitability. The community is debating whether the stock is oversold, with some anticipating a potential rebound, while others fear further declines and draw comparisons to past market corrections. Despite solid ad revenue recovery and a strong position in the AI/VR space, META struggles to maintain the explosive momentum of its peers, leading some to view it as a potential value play amidst broader tech sector strength.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss its upcoming earnings report and the recent unveiling of a new e-bike. Community members are debating the company's long-term viability, R2 launch, build quality, service center experiences, potential partnerships, and overall strategy in a competitive EV market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to anticipation surrounding the Phase 3 HOPE-3 trial data release for its DMD treatment, deramiocel, expected in mid-November. Community discussions focus on the potential for positive results, mirroring earlier trial success, and what this could mean for FDA approval and market value. The recent failure of a Sarepta DMD trial is adding extra attention as investors look for alternative therapies.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant drop following the FDA's changed stance on clinical trial data for its Huntington's disease therapy, with the community debating the reasons and potential fallout; some speculate about regulatory setbacks and compare it to other biotech firms, while others see a buying opportunity amidst the volatility. The stock's movement is heavily discussed in the context of broader biotech industry trends and potential for future acquisitions.

What is Chainlink? Chainlink is the industry-standard oracle platform bringing the capital markets onchain and powering the majority of decentralized finance (DeFi). Chainlink stands to benefit the most from emerging blockchain-industry trends, such as stablecoin adoption, real-world asset tokenization, and institutional adoption of blockchain technology. Chainlink is powered by the LINK token, which is used to pay for platform services and secure the network’s proper functioning. Chainlink leverages a novel fee model where offchain and onchain revenue from enterprise adoption is converted to LINK tokens and stored in a strategic Chainlink Reserve.   Chainlink is at the forefront of financial innovation and the global tokenization trend. Traditional financial institutions and infrastructures, such as Swift, DTCC, Euroclear, J.P. Morgan, Mastercard, Central Bank of Brazil, UBS, SBI, Fidelity International, ANZ,  and many others are adopting Chainlink as fundamental infrastructure as they move toward tokenizing trillions onchain. Demand for Chainlink has already generated hundreds of millions of dollars in revenue across a variety of traditional and decentralized use cases.   Chainlink is the only all-in-one platform that fulfills the requirements of any institutional blockchain use case. The Chainlink platform enables developers and institutions to access all the critical data, interoperability, compute, compliance, privacy, and legacy-system connectivity required for advanced blockchain applications that link the onchain and offchain worlds. Chainlink solves four fundamental problems for institutions interacting with tokenized assets:  The data problem. Tokenized assets need real-world information to be usable in transactions, such as market pricing, reference data, and proof of reserves data. Chainlink is the market leader in bringing real-world data onchain securely and accurately. The liquidity problem. Financial institutions need tokenized assets that can be securely accessed and moved across blockchain networks in order to maximize liquidity. Chainlink CCIP is the only cross-chain interoperability standard that securely connects any public or private blockchain, opening up global markets for tokenized assets. The synchronization problem. Tokenized assets must remain synchronized with legacy systems once issued across multiple chains. Chainlink is the only platform that offers reliable offchain data, system connectivity, and secure cross-chain interoperability, enabling a Unified Golden Record that stays with assets anywhere. The compliance problem. Regulated institutions require compliance enforcement capabilities such as identity verification (KYC), risk screening (AML), exploit protection, and asset-specific restrictions. The Chainlink Automated Compliance Engine extends existing financial infrastructure for identity and compliance data to blockchains and tokenized assets.  Since launch, the Chainlink standard has securely enabled tens of trillions in transaction value across dozens of blockchains and published tens of billions of verified messages onchain. Chainlink actively secures the large majority of DeFi protocols across different blockchains, with near total dominance on Ethereum. As a chain-agnostic platform with thousands of users across the world’s largest financial institutions and DeFi protocols, Chainlink accelerates the adoption of blockchain ecosystems and is used by tens of thousands of developers, including protocols such as Aave, GMX, Lido, and many more. How does Chainlink work? Chainlink is a set of open standards for onchain data, cross-chain interoperability, and offchain computation. The platform is powered by decentralized oracle networks (DONs), which are composed of independent oracle node operators that come to consensus over any arbitrary input to deliver highly secure and reliable data, computation, and value to its intended destination. Chainlink node operators include traditional Web2 telecommunication providers, leading data providers, and Web3 infrastructure providers such as Deutsche Telekom, Swisscom, Vodafone, and Infura.   The Chainlink data standard, including Data Feeds and Data Streams, is used to supply DeFi with financial market data; tokenized assets with proof of reserve (PoR), net asset value (NAV), assets under management (AUM); traditional institutions with identity and compliance data; and decentralized applications (dApps) with virtually any type of data point they need to function.  The Chainlink interoperability standard, powered by the Cross-Chain Interoperability Protocol (CCIP), enables data and value to move seamlessly across any public and private blockchain, as well as facilitates communication between blockchains and traditional systems, such as banks, governments, and enterprises. CCIP secures tens of billions of dollars in asset value and has enabled the transfer of billions of dollars in cross-chain value. The Chainlink compute standard, powered by the Chainlink Runtime Environment (CRE) enables developers to easily build an application that combines any data, any blockchain, any legacy systems, and computation into a unified application. With CRE, developers can easily adapt the application to support new connections without having to rewrite the app. What is the LINK token? LINK is the native token of the Chainlink Network, used for both payments and staking. Users can pay for Chainlink services in LINK tokens or in alternative assets (e.g., gas tokens) that are automatically converted into LINK via Payment Abstraction and stored in a strategic Chainlink Reserve. The Reserve is designed to support the long-term growth and sustainability of the Chainlink Network by accumulating LINK tokens using offchain revenue from large enterprises that are adopting the Chainlink standard and from onchain service usage, which has already generated hundreds of millions in revenue. Network service providers, such as node operators and LINK Stakers, also earn rewards in LINK tokens, which can be staked to support the cryptoeconomic security of the Chainlink Network.  The Chainlink platform supports a range of billing and payment models, including usage-based payments (e.g., subscription contracts and per-call models), revenue-sharing agreements (e.g., percentage of application revenue or recaptured MEV), Chainlink Build (i.e., a program where projects allocate a portion of their token supply), and Chainlink Scale (i.e., a program where blockchain ecosystems cover Chainlink service operating costs).  Chainlink Staking adds an additional layer of cryptoeconomic security to the Chainlink Network where LINK is staked (locked up) and can be slashed (forfeited) as a penalty if service providers fail to meet predefined performance requirements. Both node operators and community stakers play a critical role in supporting the reliability and integrity of the Chainlink Network.

ChainLink

Chainlink is trending amid discussions about its real-world utility and recent partnerships, including one with SWIFT, though some investors express frustration that the price isn't reflecting the positive news. Community members are debating whether LINK is undervalued compared to other cryptocurrencies like XRP, while also considering potential catalysts like the upcoming SmartCon event and the broader market conditions as possible drivers for future price movement.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending due to discussions around a potential bottom and upcoming Q3 earnings, with analysts projecting continued revenue growth and potential profitability. Community members are weighing the impact of a recent court case development and expressing frustration with the stock's suppressed price despite positive company performance. A new pipeline program and potential M&A activity are also being discussed as possible catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders...

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2025

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety...

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ENVB News

ENVBEnveric Biosciences Inc